Legal Research

This Week?s Biotech Highlights

By Jeremy Grushcow

A “Round 2″ edition of biotech highlights:

• Round 1 of this week’s IPOs (yep, that’s IPO with an “s”, as in more than one) was a draw, with shares of Cumberland ending flat on the day; but Round 2 — Emdeon’s offering the next day — was a knock-out, leading some (ok, me) to suggest the markets may be opening up to the idea of biopharma offerings.
• Round 2 of Amgen’s study showed that genetic differences really do correlate with response to their medicine — Vectibix — in the treatment of colorectal cancer.  Score this one for personalized medicine.

and last but not least:

• Round 2 of Richard Chan’s new and improved Friday Science Review was posted on the blog, with great items on MS, Epilepsy and DNA forensics.

Although I boxed myself in (har) and can’t fit it into the post’s theme, please check out the new mentoring program that I’ve been helping to plan, along with all the other good things that happen when the gloves come off at the Cross-Border Biotech Blog.

Full post as published by Slaw.ca on August 17, 2009 (boomark / email).